Biomarkers of Chronic Pancreatitis: A systematic literature review

Cruz‐Monserrate, Zobeida; Gumpper, Kristyn; Pita, Valentina; Hart, Phil A.; Forsmark, Christopher E.; Whitcomb, David C.; Yadav, Dhiraj; Waldron, Richard T.; Pandol, Stephen J.; Steen, Hanno; Anani, Vincent; Kanwar, Natasha; Vege, Santhi Swaroop; Appana, Savi; Liang, Li; Serrano, José; Rinaudo, Jo Ann; Topazian, Mark D.; Conwell, Darwin L.

doi:10.1016/j.pan.2021.01.006

Cited by 23 publications

(19 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 However, biomarkers of pancreatic disease are currently being sought in biofluids that do not require invasive procedures. Whereas a wide variety of potential CP biomarkers were recently evaluated, 18 practically all detected in blood samples, many of the potential saliva biomarkers we identified here have not been examined to date in other sample types.…”

Section: Discussionmentioning

confidence: 99%

Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity

Waldron

Jones

Anani³

et al. 2022

Pancreas

Self Cite

View full text Add to dashboard Cite

Objectives: Chronic pancreatitis (CP) is a chronic fibroinflammatory condition of the pancreas difficult to diagnose in early stages. Novel biomarkers useful to facilitate early diagnosis or treatment responses may be found in biofluids. Although saliva can be easily and noninvasively collected from patients, useful salivary biomarkers from CP patients have not yet been identified.Methods: Here, we analyzed the proteome by quantitative proteomics, cytokine/chemokine levels by Luminex analysis, prostaglandin E 2 (PGE 2 ) levels by a mass spectrometry-based assay, and bacterial species diversity by 16S ribosomal ribonucleic acid sequencing in saliva samples from confirmed CP patients and healthy controls. Results:Our results indicate the presence of various differentially expressed proteins, cytokines/chemokines, and a loss of oral bacterial diversity in the saliva of CP patients. The PGE 2 levels trend toward elevation in CP patients. Area under the receiver operating characteristic curve models for proteomic, cytokine, and PGE 2 assays ranged from 0.59 to 0.90. Conclusions:Collectively, our studies identify a range of putative CP biomarkers and alterations in human saliva requiring further validation. The biomarker discovery approaches we used might lead to identification of biomarkers useful for CP diagnosis and monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity

Waldron

Jones

Anani³

et al. 2022

Pancreas

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chronic pancreatitis is an important risk factor for development of pancreatic ductal adenocarcinoma and is characterized by acinar injury, damage of the gland, sustained inflammation, fibrosis, and loss of islet cells. Chronic pancreatitis manifests in unrelenting abdominal pain, malnutrition, pancreatogenic diabetes (type 3c diabetes), and exocrine and endocrine insufficiency ( Bhattamisra et al, 2019 ; Singh et al, 2019 ; Illés et al, 2020 ; Wei et al, 2020 ; Cruz-Monserrate et al, 2021 ). Risk factors include heavy alcohol abuse, tobacco smoking, and genetic predispositions ( Majumder and Chari, 2016 ; Singh et al, 2019 ).…”

Section: Inflammatory Pancreatic Diseasesmentioning

confidence: 99%

Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases

Faraoni

Robson

et al. 2022

Front. Physiol.

View full text Add to dashboard Cite

Adenosine 5'-triphosphate (ATP), other nucleotides, and the nucleoside analogue, adenosine, all have the capacity to modulate cellular signaling pathways. The cellular processes linked to extracellular purinergic signaling are crucial in the initiation, evolution, and resolution of inflammation. Injured or dying cells in the pancreatobiliary tract secrete or release ATP, which results in sustained purinergic signaling mediated through ATP type-2 purinergic receptors (P2R). This process can result in chronic inflammation, fibrosis, and tumor development. In contrast, signaling via the extracellular nucleoside derivative adenosine via type-1 purinergic receptors (P1R) is largely anti-inflammatory, promoting healing. Failure to resolve inflammation, as in the context of primary sclerosing cholangitis or chronic pancreatitis, is a risk factor for parenchymal and end-organ scarring with the associated risk of pancreatobiliary malignancies. Emerging immunotherapeutic strategies suggest that targeting purinergic and adenosinergic signaling can impact the growth and invasive properties of cancer cells, potentiate anti-tumor immunity, and also block angiogenesis. In this review, we dissect out implications of disordered purinergic responses in scar formation, end-organ injury, and in tumor development. We conclude by addressing promising opportunities for modulation of purinergic/adenosinergic signaling in the prevention and treatment of pancreatobiliary diseases, inclusive of cancer.

show abstract

“…Primarily based on the statistical discrimination tool area under the receiver operator curve (AUROC), a systemic literature review has attempted to determine which biomarkers have the greatest potential with respect to clinical translation [32]. Of 81 biomarkers studied, 61 showed only modest or moderate effect sizes, so that after subtracting the 15 biomarkers with no detected effect, only five biomarkers were categorized as promising (AUROC > 0.96).…”

Section: Biomarkers For Severity and Prognosis Assessmentmentioning

confidence: 99%

Clinical and translational markers of severity and prognosis in chronic pancreatitis

Sirtl

Beyer

Mayerle

2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewThe incidence of chronic pancreatitis as a progressive inflammation and fibrosis syndrome is on the rise due to increasing awareness and improved imaging modalities. Numerous classification systems have been suggested in recent years to describe the disease, but only few of them have been used to classify the severity and prognostic significance of the disease. Biomarkers for severity and (early) chronic pancreatitis diagnosis are not yet ready for clinical application.Recent findingsIn using the M-ANNHEIM and Chronic Pancreatitis Prognosis Score (COPPS) classification system, the severity assessment and short- and medium-term disease progression is available. A prospectively validated biomarker for early chronic pancreatitis diagnosis is not yet available, metabolome-based approaches seem to have the greatest potential for clinical translation.SummaryCurrently, due to the lack of universal definition for the early disease stage of chronic pancreatitis, it is difficult to accurately classify these patient cohorts in existing scoring systems. In principle, setting up a suitable scoring system would allow surveillance and establish a therapy approaches flanked by corresponding biomarker panel development. Therapy management of chronic pancreatitis and monitoring by means of scoring systems (such as the COPPS) would make a decisive contribution to improving patient treatment.

show abstract

Biomarkers of Chronic Pancreatitis: A systematic literature review

Cited by 23 publications

References 105 publications

Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity

Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity

Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases

Clinical and translational markers of severity and prognosis in chronic pancreatitis

Contact Info

Product

Resources

About